RevOpsis Therapeutics
PrivateLast Round
VC Round
Sep 16, 2025
Total Funding Raised
$18.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
RevOpsis Therapeutics operates in Healthcare & Life Sciences and is based in San Carlos, California. Its latest recorded funding round was a VC Round in September 2025.
RevOpsis Therapeutics is a biopharmaceutical company that develops multispecific antibody treatments for complex diseases, with an initial focus on retinal vascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RevOpsis Therapeutics Comparables
Compare RevOpsis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tavo Biotherapeutics | 84% | |
| AsclepiX Therapeutics | 83% | |
| INGENIA Therapeutics | 82% |
For institutional investors. Book with your work email.
RevOpsis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 16, 2025 | ||||
| Grant | Oct 15, 2024 | ||||
| Seed | Apr 25, 2024 |
For institutional investors. Book with your work email.
RevOpsis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Eye Institute (NIH) | Grant |
| NIH RADx | Grant |
| National Eye Institute | Grant |
| ExSight Ventures | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 134% MoM, reaching 1.5K.
- Apr 21, 2026
Monthly visitors grew 351% MoM, from 227 to 1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 9, 2026
RevOpsis Therapeutics, Inc. grants Glaukos Corporation exclusive rights to its proprietary RevMod platform in geographic atrophy, DME, DR, RVO, and nAMD for discovering and developing up to four additional next-generation retinal biologic candidates.
- is_developingOct 8, 2026
RevOpsis agrees to develop RO-104 under an exclusive license agreement in California on Oct 8th '26
For institutional investors. Book with your work email.
RevOpsis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RevOpsis Therapeutics's valuation, stock price, and market status.
Is RevOpsis Therapeutics a public or private company?
RevOpsis Therapeutics is a private company.
What is the current stock price of RevOpsis Therapeutics?
RevOpsis Therapeutics is a private company, so its shares have no public market price. Caplight tracks RevOpsis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RevOpsis Therapeutics worth (valuation)?
Valuation information for RevOpsis Therapeutics is not publicly available.
Can I buy RevOpsis Therapeutics stock?
RevOpsis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RevOpsis Therapeutics's last funding round?
RevOpsis Therapeutics's most recent funding round was VC Round on September 16, 2025.
Who are the main investors in RevOpsis Therapeutics?
Key investors in RevOpsis Therapeutics include ExSight Ventures.
Will RevOpsis Therapeutics IPO soon?
No public IPO plans have been announced for RevOpsis Therapeutics.
How can I track RevOpsis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in RevOpsis Therapeutics's shares on secondary markets.